Metanx Lowers Risk of Hospitalization and Disease-Related Costs
PamLab announced that a study published in The American Journal of Pharmacy Benefits demonstrates the effects of Metanx (L-methylfolate, pyridoxal 5'-phosphate, methylcobalamin tablets) on commercially insured patients with diabetic peripheral neuropathy (DPN).
The retrospective study compared a total of 814 patients with DPN, of which one group was prescribed Metanx. The study showed that patients in the Metanx treatment group had lower risks of hospitalization during the 12-month follow up period. In addition, the Metanx treatment group was shown to have an average of $2,258 lower disease-related costs than the non-Metanx group.
Metanx, a prescription medical food, is indicated as adjunct in endothelial dysfunction, hyperhomocysteinemia, atherosclerotic vascular disease, and vitamin B12 deficiency.
For more information call (985) 893-4097 or visit www.metanx.com.